Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05355766Phase 2Completed

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

Role: lead

NCT04614779Phase 2Completed

Long-term Clinical Study of CN128 in Thalassemia Patients

Role: lead

NCT03935633Phase 1Completed

Short-term Clinical Study of CN128 in Thalassemia Patients

Role: lead

NCT03673085Phase 1Completed

Clinical Study of CN128 in Thalassemia Patients

Role: lead

All 4 trials loaded